The High-Flow Nasal Cannula (HFNC) Hybridization
In 2026, the distinction between "CPAP/BiPAP" and "High Flow" has blurred into a single, integrated platform.
Seamless Transitions: Top-tier units like the Fisher & Paykel Airvo 3 allow clinicians to switch between traditional BiPAP and High-Flow Nasal Cannula (HFNC) therapy without changing the device or the circuit.
Humidity Control: Advanced sensors now adjust the temperature and saturation of the air in real-time, matching the patient’s exact core temperature to maximize comfort—a critical factor in 2026 for maintaining patient compliance during 24/7 long-term use.
Early Intervention: HFNC is now the gold standard in 2026 for "pre-emptive" support in the ER, preventing the need for more aggressive ventilation in up to 40% of acute respiratory cases.